Phaseline

Targets › IL13

IL13 (Interleukin-13): drug programs, companies and trials

5 programs from 5 companies in 20 trials: 13 Phase 3, 4 Phase 2, 2 Phase 4, 1 Phase 1; Immunology, Respiratory, Other; next expected readout Nov 2026.

Cytokine that plays important roles in allergic inflammation and immune response to parasite infection. Synergizes with IL2 in regulating interferon-gamma synthesis. (UniProt, P35225)

Open in Phaseline: the race on IL13, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Eli LillyLebrikizumab (LY3650150)
Interleukin-13 inhibitor
IL13Phase 4Atopic Dermatitis; Chronic Rhinosinusitis With Nasal Polyps (CRSwNP); Perennial Allergic Rhinitis (PAR)Dec 2026
Pfizertilrekimig (PF-07275315)
IL-13 receptor alpha-1 antagonist
IL13Phase 3Atopic Dermatitis; Asthma; Moderate to Severe Chronic Obstructive Pulmonary Disease; HealthyNov 2026
AlmirallLebrikizumab
Interleukin-13 inhibitor
IL13Phase 3Dermatitis, Atopic; Nummular EczemaApr 2027
AstraZenecaTozorakimab Dose Regimen 1
IL-13 receptor antagonist
IL13Phase 3Viral Lung Infection and Acute Respiratory Failure; Chronic Obstructive Pulmonary Disease; AsthmaJun 2027
LEO PharmaTralokinumab
Interleukin-13 inhibitor
IL13Phase 3Atopic DermatitisApr 2028

Conditions

Atopic Dermatitis (8) Asthma (4) Chronic Rhinosinusitis With Nasal Polyps (CRSwNP) (1) Perennial Allergic Rhinitis (PAR) (1) Moderate to Severe Chronic Obstructive Pulmonary Disease (1) Healthy (1) Dermatitis, Atopic (1) Nummular Eczema (1) Viral Lung Infection and Acute Respiratory Failure (1) Chronic Obstructive Pulmonary Disease (1)

Modalities

antibody (4), mixed (1)

Companies

Eli Lilly (1) Pfizer (1) Almirall (1) LEO Pharma (1) AstraZeneca (1)

Related targets

–

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.